[The use of katadolon in patients with spondylogenic dorsalgia].
The open non-comparative study of the efficacy of katadolon (100 mg 3 times daily during 2 weeks) in 90 out-patients with spondylogenic dorsalgia has been carried out. A good effect, i.e. the complete relief of the pain syndrome, rehabilitation of the ability to self-service and regress of neurological symptoms, was observed in 59 (65.6%) patients, a satisfactory effect, i.e. the complete relief of the pain syndrome with elements of restricted daily activity and symptoms of radiculopathy-- in 24 (26.7%) patients and a moderate effect, i.e. the presence of the residual pain syndrome, restricted daily activity and symptoms of radiculopathy,--in 7 (7.8%) patients. After the therapy, the intensity of the pain syndrome decreased by 4 times, from 69.7 +/- 4.3 to 17.6 +/- 0.11 according to the numerical scale of pain (p < 0.01), and by 2.5 times, from 2.51 +/- 0.27 to 1.04 +/- 0.09 (p < 0.0001), according to the verbal scale of pain. At the same time, the ability to self-service increased by 3 times on the daily living scale (2.6 +/- 0.28; p < 0.0001). At the end of the treatment, the intensity of the pain syndrome was associated with illness duration (r = 0.538; p < 0.01) and the presence of the root pain syndrome (r = 0.266; p < 0.03). The drug was well-tolerable and caused minimal side-effects.
Kamchatnov
P R
PR
Btysheva
T T
TT
Ganzhula
P A
PA
Gaponova
O V
OV
Zhuravleva
E Iu
EIu
Ismailov
A M
AM
Kostenko
E V
EV
Boĭko
A N
AN
D000328:Adult; D000368:Aged; D000631:Aminopyridines / Q000627:therapeutic use*; D000700:Analgesics / Q000627:therapeutic use*; D001416:Back Pain / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D012720:Severity of Illness Index; D013128:Spinal Osteophytosis / Q000150:complications*; D016896:Treatment Outcome
D000631:Aminopyridines; D000700:Analgesics; C034161:flupirtine